Publication Name	World Journal of Rheumatology
Manuscript ID	13041
Country	Spain

Received	2014-08-03 09:58
Peer-Review Started	2014-08-03 11:05
To Make the First Decision	2014-08-28 14:44
Return for Revision	2014-09-03 15:32
Revised	2014-09-08 00:45
Second Decision	2015-03-20 11:50
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-04-07 15:44
Articles in Press	2015-04-07 15:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-06-23 12:13
Publish the Manuscript Online	2015-07-08 09:04

ISSN	2220-3214 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Rheumatology
Manuscript Type	Minireviews
Article Title	Safety of biologic therapies during pregnancy in women with rheumatic disease
Manuscript Source	Invited Manuscript
All Author List	Natalia Mena-Vazquez, Sara Manrique-Arija and Antonio Fernandez-Nebro
Funding Agency and Grant Number
Corresponding Author	Antonio Fernandez-Nebro, PhD, Department of Rheumatology, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Plaza del Hospital Civil s/nPabellón 7 – 2ª planta, 29009 Málaga, Spain. afernandezn@uma.es
Key Words	Pregnancy; Biologic therapy; Monoclonal antibodies; Rheumatic diseases; Safety
Core Tip	Biologic therapy during pregnancy is an important topic that remains unresolved. Most of the monoclonal antibodies are actively transferred to fetal circulation using the neonatal Fc receptor. Some evidence suggests that differences may exist between drugs relating to safety associated with structure and the capacity to cross the placenta, but we are not aware of any study that supports this statement. Although the clinical data to date are promising, no firm conclusions can be drawn about the safety of biologic drugs during pregnancy, and, without further evidence, guidelines that suggest these drugs should be avoided at the time of conception cannot yet be changed.
Publish Date	2015-07-08 09:04
Citation	Mena-Vazquez N, Manrique-Arija S, Fernandez-Nebro A. Safety of biologic therapies during pregnancy in women with rheumatic disease. World J Rheumatol 2015; 5(2): 82-89
URL	http://www.wjgnet.com/2220-3214/full/v5/i2/82.htm
DOI	http://dx.doi.org/10.5499/wjr.v5.i2.82

Full Article (PDF)	WJR-5-82.pdf
Full Article (Word)	WJR-5-82.doc
Manuscript File	13041-Review.docx
Answering Reviewers	13041-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13041-Conflict-of-interest statement.pdf
Copyright License Agreement	13041-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	13041-Language certificate.pdf
Peer-review Report	13041-Peer-review(s).pdf
Scientific Misconduct Check	13041-Scientific misconduct check.pdf
Scientific Editor Work List	13041-Scientific editor work list.pdf